described use of postoperative lymphatic exudate and plasma in stage III melanoma patients as a way to collect biomarkers including factors not only associated with melanoma (LDH, S100B, S100A8) but also linked to metastatic potential (CSF-1, galectin-3, MMP2- MM-9). The gene discussed is S100A8; the disease is melanoma.